From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
MET Inhibitor | ||||
---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Bozitnib (APL-101) | c-MET receptor (HGFR) Inhibitor | NCT03175224 (1/2) | Monotherapy | c-MET altered solid tumors including NSCLC |
Capmatinib (INC280) | MET Inhibition through HGFR binding | NCT04139317 (2) | Combination with Pembrolizumab | EGFR wild type and ALK negative NSCLC with high PDL1 expression |
Capmatinib (INC280) | MET Inhibition through HGFR binding | NCT02414139 (2) | Monotherapy | EGFR wild type and ALK negative NSCLC with cMET alteration |
Glumetinib | Small molecule MET kinase Inhibitor | NCT04338243 (1/2) | Monotherapy | T790M Mutation negative and Met amplified NSCLC |
REGN5093 | Bispecific antibody that Inhibits MET | NCT04077099 (1/2) | Monotherapy | MET altered NSCLC |
Tepotinib | Selective MET inhibitor | NCT03940703 (2) | Combination with Osimertinib | MET amplified NSCLC with EGFR mutation |
TFX-0022 | MET, CSF1R, SRC kinase Inhibitor | NCT03993873 (1) | Monotherapy | NSCLC with MET alterations |